Mechanism of action
Bremelanotide is a synthetic cyclic heptapeptide derived structurally from the natural ligand alpha-melanocyte-stimulating hormone (alpha-MSH). It was developed from melanotan II by removal of the C-terminal amide group, and it carries a lactam bridge that locks its conformation into a stable ring. The molecular weight is 1025.2 daltons. The cyclic structure plus non-standard residues (norleucine, D-phenylalanine) make the molecule notably resistant to enzymatic degradation compared with linear melanocortin peptides.
Mechanistically, bremelanotide is a non-selective agonist at the melanocortin receptor family. The FDA label characterizes its binding-affinity order as MC1R > MC4R > MC3R > MC5R > MC2R [9]. The therapeutically relevant receptor for the sexual-desire effect is understood to be MC4R, which is densely expressed in the medial preoptic area (mPOA) of the hypothalamus and in adjacent limbic regions [5].
In the proposed model, MC4R activation in the mPOA triggers downstream dopamine release in central sexual-response circuits. A 2022 neurobiology review by Pfaus and colleagues synthesizes the preclinical and human data behind that hypothesis and characterizes bremelanotide as a centrally acting melanocortin agonist whose desire-domain effects are mediated by hypothalamic and limbic dopaminergic activity, not by peripheral vasodilation [5].
A 2025 study in female Syrian hamsters added a nuance to this picture. The researchers confirmed that MC4R messenger RNA is concentrated in ventral tegmental area dopamine neurons, but bremelanotide treatment did not change melanocortin receptor expression in the mesolimbic dopamine pathway, and bremelanotide did not enhance sexual reward in a conditioned place preference paradigm [6]. The authors interpret this as evidence that the mesolimbic reward circuit may not be the primary site of clinical action — that desire and reward, at least in this model, dissociate.
The RECONNECT Phase 3 trials
Two identically designed, randomized, double-blind, placebo-controlled trials — RECONNECT 301 and RECONNECT 302 — make up the pivotal efficacy evidence. The combined trials randomized 1,267 premenopausal women with acquired, generalized HSDD [1].
The co-primary endpoints were change from baseline at 24 weeks on the FSFI-D (Female Sexual Function Index — Desire domain) and on FSDS-DAO Item 13 (a single-item distress measure focused specifically on low sexual desire). Both endpoints reached statistical significance versus placebo in both studies.
On FSFI-D, the improvement over placebo was 0.30 in study 301 (p<0.001) and 0.42 in study 302 (p<0.001) [1]. On FSDS-DAO Item 13, women on bremelanotide reported significantly larger reductions in distress about low desire than women on placebo, in both studies.
A 2022 narrative review summarized the integrated responder rates: roughly 58% of women on bremelanotide met FSFI-D responder criteria, versus roughly 35% on placebo. Satisfying sexual events increased by approximately 25% on bremelanotide versus approximately 10% on placebo [14].
A prespecified subgroup analysis of the integrated RECONNECT dataset (n=1,202) examined whether the treatment effect held across age, body mass index, baseline testosterone, contraceptive use, and HSDD duration. It did — the benefit was preserved across these clinically meaningful subgroups [4].
Long-term follow-up
After the 24-week double-blind period, RECONNECT participants were offered a 52-week open-label extension on the 1.75 mg dose [2]. Enrollment in the extension was 684 women; 272 completed the full year.
Improvements in FSFI-D and FSDS-DAO were sustained over the year of as-needed dosing, and no new safety signals emerged relative to the double-blind period [2]. The extension is the longest published prospective safety dataset on bremelanotide.
A broader integrated safety analysis published in 2022 pooled data from across the clinical development program — 43 completed studies and approximately 3,500 subjects — and characterized the adverse event profile as generally mild to moderate, dominated by nausea and flushing [3].
Pharmacokinetics
Bremelanotide is administered subcutaneously, and bioavailability by that route is reported at approximately 100% [9]. Time to peak plasma concentration (Tmax) is approximately 1 hour (range 0.5 to 1.0 hours). Peak plasma concentration (Cmax) is approximately 72.8 ng/mL and the area under the curve (AUC) is approximately 276 hr*ng/mL. Plasma protein binding is approximately 21%.
The terminal half-life in plasma is approximately 2.5 to 2.7 hours (range approximately 1.9 to 4.0 hours). Elimination is primarily renal (approximately 64.8% urinary) with approximately 22.8% fecal excretion.
In a Phase 2b dose-ranging study, three subcutaneous doses (0.75, 1.25, and 1.75 mg) were compared. The 1.75 mg dose was selected for Phase 3 development based on a responder analysis that weighed efficacy across FSFI-D and FSDS-DAO endpoints against the adverse event profile [15]. Earlier Phase 2 work had also evaluated an intranasal formulation [12], but that route was abandoned because of post-dose blood pressure increases.
Safety and tolerability
The dominant tolerability finding is nausea. In the integrated safety dataset, nausea occurred in 40.0% of subjects on the 1.75 mg dose [3]. Flushing was reported in 20.3%, headache in 11.3%, and injection-site reactions in 13.2% (most mild). Approximately 8% of subjects discontinued the drug specifically because of nausea.
Focal hyperpigmentation — localized darkening of skin or mucous membranes, most often on the face, gingiva, or breasts — was reported in approximately 1% of patients in the RECONNECT trials [11]. The mechanism is thought to be off-target MC1R activation on melanocytes. Risk appears to increase with darker skin types and with more frequent dosing. The label notes that hyperpigmentation may not fully resolve after discontinuation [11].
A dedicated ambulatory blood pressure monitoring study in 397 premenopausal women characterized the drug's cardiovascular signal. Bremelanotide produced small, transient post-dose increases in systolic blood pressure (2.4 to 3.2 mmHg versus placebo) that peaked within four hours after dosing and resolved within twelve hours [8]. The investigators concluded that the magnitude was not clinically important in healthy subjects, but the finding underwrites the label's caution against use in patients with uncontrolled hypertension or known cardiovascular disease [9].
The label also describes a clinically meaningful drug interaction: when bremelanotide was co-administered subcutaneously with oral naltrexone, naltrexone Cmax fell by approximately 60% and AUC by approximately 40% [10]. The mechanism is thought to be slowed gastric emptying. Concomitant use with oral naltrexone for alcohol or opioid use disorder is therefore not recommended.
Recent research, 2024 and 2025
Several recent publications have extended or contextualized the bremelanotide record. The 2025 recommendations from the 5th International Consultation on Sexual Medicine (ICSM) reviewed available pharmacotherapies for HSDD and endorsed bremelanotide as an as-needed option for premenopausal women with HSDD, with moderate evidence support, citing nausea, flushing, and headache as the most common adverse events and contraindication in uncontrolled hypertension [13].
A 2024 in vitro study reported that bremelanotide reduced expression of the anti-apoptotic protein survivin and induced cell death in glioblastoma cell lines at concentrations non-toxic to normal human cells, with effects mediated through MC3R and MC4R [7]. This finding is preclinical and exploratory; it does not translate to any clinical recommendation.
Palatin Technologies, the original developer, has reported press-release-level results from two investigational programs outside the approved HSDD indication. A 2025 Phase 2 obesity study (BMT-801) co-administered low-dose bremelanotide with the dual GIP/GLP-1 agonist tirzepatide and reported that the combination met its primary appetite-suppression endpoint, with low-dose bremelanotide preventing post-tirzepatide weight regain in an 8-week trial [16]. A separate Phase 2 study initiated in 2024 evaluates bremelanotide co-administered with a PDE5 inhibitor in men with erectile dysfunction who are non-responders to PDE5 monotherapy [17]. Both programs are investigational, not FDA-approved, and outside the scope of the current approved label.